Cellebrite reported FY 2025 revenue of USD 475.7 million, up 19% year over year, driven by continued sales of its Inseyets digital forensics software and broader adoption of offerings including Pathfinder and Guardian. Net income for FY 2025 was USD 78.3 million, compared with a net loss in FY 2024, which the company said primarily reflected the impact of fair-value remeasurement of warrants and share-related liabilities in the prior year. Adjusted EBITDA for FY 2025 was USD 127.6 million, up 28.4% year over year. Annual recurring revenue $(ARR)$ ended FY 2025 at USD 481 million (+21% year over year), while recurring revenue dollar-based net retention was 116%. Operating cash flow in FY 2025 was USD 173.5 million and free cash flow was USD 160.3 million. Cash, cash equivalents, short-term deposits and marketable securities totaled USD 535.0 million as of December 31, 2025. Cellebrite also highlighted its acquisition of Corellium Inc. for a net payment of USD 147.5 million during FY 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-013790), on March 03, 2026, and is solely responsible for the information contained therein.
Comments